A Safety and Efficacy Study of HCB101, Fc-fusion Protein Targeting SIRPα-CD47 Pathway, in Solid or Hematological Tumors

This early-phase safety study tests HCB101, a new drug designed to help the immune system recognize and attack cancer cells by blocking a "do not eat me" signal (the CD47-SIRPα pathway), in people with advanced solid tumors or blood cancers. **You may be eligible if...** - You are 18 or older - You have a solid tumor or blood cancer confirmed by biopsy that has stopped responding to standard treatments - You are willing to provide tissue for analysis **You may NOT be eligible if...** - Your cancer still has available standard treatment options - You are unable to give informed consent - You have conditions that make participation unsafe Talk to your doctor to see if this trial is right for you.